Merck & Co., Inc. $MRK Stock: Allianz SE Boosts Holdings

Allianz SE boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 10.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 123,395 shares of the company’s stock after acquiring an additional 11,187 shares during the period. Allianz SE’s holdings in Merck & Co., Inc. were worth $17,931,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. State Street Corp boosted its holdings in shares of Merck & Co., Inc. by 0.8% in the third quarter. State Street Corp now owns 121,422,392 shares of the company’s stock valued at $17,745,131,000 after acquiring an additional 1,009,136 shares during the period. Cornerstone Select Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 2.8% in the 3rd quarter. Cornerstone Select Advisors LLC now owns 26,249 shares of the company’s stock valued at $3,814,000 after acquiring an additional 726 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its stake in Merck & Co., Inc. by 90.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,784 shares of the company’s stock worth $259,000 after purchasing an additional 845 shares during the period. Sumitomo Life Insurance Co. boosted its stake in Merck & Co., Inc. by 150.5% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 57,534 shares of the company’s stock worth $8,360,000 after purchasing an additional 34,566 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in Merck & Co., Inc. by 69.5% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company’s stock worth $32,000 after purchasing an additional 91 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on MRK shares. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a research note on Tuesday, September 29th. Cantor Fitzgerald increased their target price on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Royal Bank Of Canada lowered their price target on Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating on the stock in a report on Friday, October 30th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Finally, Freedom Broker upped their price objective on Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a research note on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $155.74.

View Our Latest Report on MRK

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $133.56 on Friday. The firm has a market capitalization of $329.26 billion, a PE ratio of 46.30, a P/E/G ratio of 6.62 and a beta of 0.13. Merck & Co., Inc. has a 52 week low of $95.36 and a 52 week high of $156.92. The firm’s 50-day simple moving average is $145.28 and its 200 day simple moving average is $129.29. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same quarter in the prior year, the company earned $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. On average, equities research analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.52 annualized dividend and a dividend yield of 2.6%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio is 350.52%.

Insider Activity at Merck & Co., Inc.

In other news, EVP Richard Deluca sold 58,185 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the transaction, the executive vice president owned 112,955 shares of the company’s stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.17% of the stock is currently owned by company insiders.

Merck & Co., Inc. News Summary

Here’s some of the latest news about MRK:

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.